Observational Study of 19F MRI for Cystic Fibrosis Lung Function
This observational study is looking at how lung ventilation changes over one year in people with cystic fibrosis (CF). Researchers will use a special type of MRI called 19F MRI, which involves inhaling a harmless gas called perfluoropropane, to measure lung function. These measurements will be compared to other standard lung tests. The study also aims to see how these measures change if you experience a flare-up of your CF symptoms (pulmonary exacerbation) and receive treatment. You may be eligible if you are 18 years or older, a non-smoker, have a CF diagnosis, don't use supplemental oxygen, and have stable lung function. The study hopes to enroll 30 participants. Success would mean understanding how these lung measurements change over time and in response to exacerbations.
- Study design
- This is an observational study, meaning it looks at changes over time without assigning specific treatments. It plans to enroll 30 participants.
- What's involved
- You would complete 3 to 5 visits to the University of North Carolina at Chapel Hill (UNC) over one year, with each visit lasting up to 4 hours.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for changes in lung function over 14 days and up to 365 days.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Jennifer L Goralski, MD · PRINCIPAL_INVESTIGATOR · UNC Chapel Hill
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in Ventilation Defect Parameter (VDP) over 14 daysDay 1 to Day 14
VDP measured at Day 1 and Day 14, expressed as a percentage of total lung volume
- Change in VDP over 365 daysDay 1 to Day 365 (+/- 30 days)
Average of VDP measured at Day 1 and Day 14; subtracted from VDP at Day 365, expressed as a percentage of total lung volume
- Change in FLVlongtau2 over 14 daysDay 1 to Day 14
FLVlongtau2 measured at Day 1 and Day 14, expressed as a percentage of total lung volume
- Change in FLVlongtau2 over 365 daysDay 1 to Day 365 (+/- 30 days)
Average of FLVlongtau2 measured at Day 1 and Day 14; subtracted from FLVlongtau2 at Day 365, expressed as a percentage of total lung volume
- Change in VDP occurring with a protocol-defined CF pulmonary exacerbationDay 1 to Day 365 (+/- 30 days)
Difference in VDP between baseline and exacerbation visit 1, expressed as a percentage of total lung volume.
- Change in FLVlongtau2 occurring with a protocol-defined CF pulmonary exacerbationDay 1 to Day 365 (+/- 30 days)
Difference in FLVlongtau2 between baseline and exacerbation visit 1, expressed as a percentage of total lung volume.